Patients enrolled IMPACTA STUDY N=3,365

Evaluable sample N=2,038

Previous antimuscarinic therapy (mono or combined) N=1,407

Prior tolterodine therapy N=911

Prior tolterodine as a 1st therapy of OAB N=842

Switch

Excluded due to enrollment criteria violation N=1,327

Fesoterodine: 748
- 4 mg: 226 (30.2%)
- 8 mg: 509 (68.0%)
- Unknown: 13 (1.7%)

Fesoterodine: 748
- <65 years: 418 (55.9%)
- >65 years: 330 (44.1%)